PHENYLEPHRINE HYDROCHLORIDE READY-TO-USE SOLUTION
This invention relates to a dilute, ready-to-use solution of phenylephrine hydrochloride having improved stability and utility. In a particular embodiment, the formulation consists of an injectable form of phenylephrine hydrochloride with edetate disodium chelating agent in place of any sodium metabisulfite antioxidants to improve the solution's ability to remain stable and active in a dilute state after prolonged storage. This invention also relates to a form for injection of the solution that includes packaging the solution in a single-use container, as well as a form for containing the ready-to-use solution in a sterile, sealed container. Lastly this invention relates to methods of making the injectable solution for use in a single-use container, as well as for containment in a sterile, sealed container.
1 . A stable, ready-to-use sterile intravenous injection solution of phenylephrine hydrochloride packaged into a vial for injection, wherein the solution comprising:
from about 0.05 mg/mL to about 0.15 mg/mL phenylephrine hydrochloride as the only active pharmaceutical ingredient in the solution;
from about 0.1 mg/mL to about 0.3 mg/mL of edetate disodium (EDTA);
sodium chloride; and
water;
wherein the solution has a pH between 3 and 6.5, is stored in a single use vial, and exhibits 0.2% or less of phenylephrine impurities after exposure to a temperature of 40° C. for a period of 6 months; and wherein the solution is free of bisulfites or other antioxidants.
2 . A stable, ready-to-use sterile intravenous injection solution of phenylephrine hydrochloride packaged into a vial for injection, wherein the solution comprising:
from about 0.05 mg/mL to about 0.15 mg/mL phenylephrine hydrochloride as the only active pharmaceutical ingredient in the solution;
from about 0.1 mg/mL to about 0.3 mg/mL of edetate disodium (EDTA);
one or more of a preservative, a buffer and/or a pH adjustor;
sodium chloride; and
water;
wherein the solution has a pH between 3 and 6.5, is stored in a single use vial, and exhibits 0.2% or less of phenylephrine impurities after exposure to a temperature of 40° C. for a period of 6 months; and
wherein the solution is free of bisulfites or other antioxidants.
3 . The solution of claim 2 , wherein the preservative is present and comprises benzyl alcohol, chlorobutanol, paraben, phenol sorbic acid or a combination thereof.
4 . The solution of claim 2 , wherein the buffer is present and is a citrate buffering system for assisting in maintaining the pH of the solution.
5 . The solution of claim 2 , wherein the pH adjuster is present and is hydrochloric acid, sodium hydroxide or both.
6 . The solution of claim 1 which exhibits about 0.1% or less of phenylephrine impurities after exposure to a temperature of 40° C. for a period of 6 months.
7 . The solution of claim 1 which has:
phenylephrine hydrochloride in an amount of about 0.1 mg/mL; and
edetate disodium in an amount of about 0.2 mg;
with the solution having a pH of from 5 to 5.3.
8 . The solution of claim 7 , wherein one or more of the following are present:
benzyl alcohol in an amount of about 8 mg/mL,
a buffering system for assisting in maintaining the pH of the solution, and/or
hydrochloric acid, sodium hydroxide or both for pH adjustment, if necessary.
9 . A sterile liquid pharmaceutical product that includes a stable, ready-to-use sterile intravenous injection solution of phenylephrine hydrochloride packaged into a vial for injection, the vial having less than 10% by volume oxygen content in a head space of the vial, wherein the solution comprising:
from about 0.05 mg/mL to about 0.15 mg/mL phenylephrine hydrochloride as the only active pharmaceutical ingredient in the solution;
from about 0.1 mg/mL to about 0.3 mg/mL of edetate disodium (EDTA);
sodium chloride; and
water;
wherein the solution has a pH between 3 and 6.5, is stored in a single use vial, and exhibits 0.2% or less of phenylephrine impurities after exposure to a temperature of 40° C. for a period of 6 months; and wherein the solution is free of bisulfites or other antioxidants.
10 . The product of claim 9 , wherein the solution is present in the vial in an amount of 0.05 to 20 mL and the head space has an oxygen content of less than 5% by volume.
11 . The product of claim 9 , wherein the solution is present in an amount that allows only a single use of the vial.
12 . A method for making the stable, ready-to-use injection solution of phenylephrine hydrochloride according to claim 1 , which comprises admixing from about 0.05 mg/mL to about 0.15 mg/mL phenylephrine hydrochloride; from about 0.1 mg/mL to about 0.3 mg/mL of edetate disodium; sodium chloride; and water for injection q.s. to form the stable, ready-to-use injection solution.
13 . The method of claim 12 that further comprises filling a vial with from about 0.05 to about 20 mL of the solution.
14 . The method of claim 13 , which further comprises providing the head space of the vial with an oxygen content that is below 10%.
15 . The method of claim 14 , wherein the oxygen content of the head space of the vial is below 5% by volume and is provided by adding nitrogen to the vial.
16 . The method of claim 13 , which further comprises providing an amount of the solution that allows only a single use of the vial.
17 . A sterile liquid pharmaceutical product that includes the solution of claim 2 packaged into the vial for injection.
18 . The solution of claim 1 , which further consists essentially of one or more of a preservative, a buffer and/or a pH adjustor.
19 . (canceled)
20 . (Canceled)
21 . (canceled)